Ingevity (NGVT) Projected to Release Quarterly Earnings on Wednesday

Ingevity (NYSE:NGVT) is expected to be releasing its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to post earnings of $1.31 per share and revenue of $312.20 million for the quarter. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 10:00 AM ET.

Ingevity (NYSE:NGVT) last announced its earnings results on Wednesday, May 6th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.84 by $0.31. Ingevity had a positive return on equity of 207.82% and a negative net margin of 10.55%.The company had revenue of $258.00 million for the quarter, compared to analysts’ expectations of $254.73 million. During the same quarter in the prior year, the business earned $1.01 earnings per share. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, analysts expect Ingevity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Ingevity Stock Performance

Shares of NYSE:NGVT opened at $73.28 on Monday. The business has a fifty day moving average of $71.08 and a 200-day moving average of $70.69. The company has a debt-to-equity ratio of 27.83, a quick ratio of 0.92 and a current ratio of 1.42. Ingevity has a twelve month low of $39.74 and a twelve month high of $79.29. The firm has a market cap of $2.55 billion, a PE ratio of -20.64 and a beta of 1.16.

Insider Activity

In other news, SVP Terrance M. Dyer sold 496 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $68.49, for a total value of $33,971.04. Following the completion of the sale, the senior vice president directly owned 7,202 shares of the company’s stock, valued at $493,264.98. This represents a 6.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.88% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Advisory Services Network LLC increased its stake in Ingevity by 4.4% in the third quarter. Advisory Services Network LLC now owns 6,947 shares of the company’s stock valued at $383,000 after purchasing an additional 293 shares in the last quarter. Amundi boosted its position in shares of Ingevity by 4.8% during the third quarter. Amundi now owns 6,626 shares of the company’s stock worth $364,000 after purchasing an additional 302 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Ingevity by 85.8% during the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares in the last quarter. Global Retirement Partners LLC acquired a new position in shares of Ingevity in the 4th quarter valued at $27,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of Ingevity by 1.6% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 30,116 shares of the company’s stock valued at $1,782,000 after buying an additional 485 shares during the period. Institutional investors and hedge funds own 91.59% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of Ingevity from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ingevity in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.